LONDON — Meatly announced a series of achievements in its scientific production process, which will allow the company to further expand its cultivated meat production and reach price parity with traditionally raised chicken.
원본 콘텐츠
The company has completed the startup and first cell growth cycle in its new low-cost, 320-liter pilot-scale bioreactor. The patented bioreactor, designed internally by Meatly's R&D team, offers the biocompatibility, durability, scalability, and overall performance that the company needs for cellular cultivation in industrial production. It will replace the use of biopharmaceutical bioreactors, which have a high price and have been a significant barrier for many cultivated meat companies. The new bioreactor costs Meatly £12,500 (approximately $16,897 USD), compared to traditional bioreactors, which can cost around £250,000 (approximately $337,947 USD), representing a cost reduction of approximately 95%. Based on this new bioreactor, Meatly plans to develop multiple 20,000-liter bioreactors to increase Meatly Chicken production. Additionally, Meatly announced that it has further reduced the cost of its protein medium, used to create its cultivated chicken ingredient, to £0.22 (30¢ ...